Total Neoadjuvant Therapy (TNT)

Strategy for locally advanced Rectal Cancer: deliver all planned chemotherapy and radiotherapy before surgery (rather than the traditional split of neoadjuvant chemoradiotherapy → surgery → adjuvant chemotherapy). Goals: tumor downstaging, eradication of distant micrometastases, and — increasingly — organ preservation via non-operative management (NOM) for strong responders.

Originally built from a single secondary review; now cross-validated against the primary publications of all four headline phase III TNT trials — Bahadoer 2021 - RAPIDO Trial, Conroy 2024 - PRODIGE 23 Long-Term Results, Jin 2022 - STELLAR Trial, and Ciseł 2019 - POLISH II Long-Term Results — plus Schrag 2023 - PROSPECT Trial, a related but distinct radiation-omission trial in a lower-risk population, and Dijkstra 2023 - RAPIDO 5-Year Locoregional Failure, RAPIDO's extended follow-up. The TNT trials disagree with each other on the locoregional-recurrence trade-off (see Efficacy below): RAPIDO now shows a confirmed, statistically significant local-control cost at 5 years, PRODIGE 23 and STELLAR show numerically better local control, and POLISH II shows no difference in either direction — flagged explicitly as a real, RAPIDO-specific finding rather than a class effect. Now also grounded, via ASCRS Ch26 - Rectal Cancer Neoadjuvant Therapy, in the history and foundational trials that established preoperative radiotherapy in the first place, in the evidence around concurrent chemoradiation regimens, and — most substantively — in the induction-vs- consolidation chemotherapy sequencing question within TNT regimens (see the new sections below).

History and foundational trials

The trials below (per ASCRS Ch26 - Rectal Cancer Neoadjuvant Therapy) predate or sit outside the four headline TNT trials above — they established preoperative radiotherapy itself, and short- vs. long-course dosing, rather than testing TNT specifically. Rectal Cancer's "Evolution of treatment" section already covers the German Rectal Cancer Study (preop vs. postop CRT, established preop CRT's lower local-recurrence and toxicity, plus higher sphincter-preservation rates) from the Sabiston chapter — not repeated here.

Swedish Rectal Cancer Trial: established that short-course preoperative radiotherapy reduces local recurrence (and improves survival) compared with surgery alone — one of the foundational trials for preoperative radiation in rectal cancer, predating routine TME.
Dutch Colorectal Cancer Group trial: tested short-course preoperative radiotherapy in combination with TME (rather than TME alone) — established that even with a high-quality mesorectal excision, adding preoperative radiotherapy further reduces local recurrence.
Original Polish trial (short- vs. long-course radiotherapy, pre-dating Ciseł 2019 - POLISH II Long-Term Results) and the Trans-Tasman Radiation Oncology Group (TROG) trial: both compared short-course radiotherapy against long-course chemoradiotherapy directly (not short-course + consolidation chemo as in POLISH II) and found no significant difference in local recurrence between the two approaches, though toxicity and sphincter-preservation profiles differed.
Stockholm III: examined the timing of surgery after short-course radiotherapy — immediate surgery vs. a delayed interval — informing how much of a gap is safe/beneficial between SCRT and surgery, relevant to this page's existing "Sequence and timing" guidance on SCRT-to-surgery intervals.
FOWARC (Chinese trial): compared standard fluorouracil-based CRT, modified-FOLFOX-based CRT, and FOLFOX chemotherapy alone (without radiotherapy) — part of the same broader evidence base, along with Schrag 2023 - PROSPECT Trial, probing whether radiotherapy can be selectively omitted or substituted with more intensive chemotherapy.

Concurrent chemoradiation regimen trials

Per ASCRS Ch26 - Rectal Cancer Neoadjuvant Therapy, these trials tested whether adding a second cytotoxic or biologic agent to standard fluoropyrimidine-based (5-FU or capecitabine) CRT improves outcomes — relevant because the CRT backbone used throughout the TNT trials above is itself fluoropyrimidine-based, largely unchanged by this line of research:

Lyon R0-04: examined interval-to-surgery effects within a chemoradiation protocol.
CALGB 89901 and ECOG 3204 (the latter adding bevacizumab to CRT): tested treatment intensification with additional/biologic agents.
STAR-01 and NSABP R-04: both tested adding oxaliplatin to fluoropyrimidine-based CRT and found no benefit, with added toxicity.
German CAO/ARO/AIO-04: also tested adding oxaliplatin to fluoropyrimidine-based CRT, but reportedly found a disease-free-survival benefit.

Flag — cross-trial inconsistency, not resolved here: STAR-01 and NSABP R-04 found no benefit (and added toxicity) from adding oxaliplatin to CRT, while German CAO/ARO/AIO-04 reportedly found a DFS benefit from the same addition. The chapter does not fully reconcile this discrepancy, and none of these four trials are independently ingested from primary publications on this wiki — reported here as textbook-secondary-source-level information, not adjudicated. Net practical effect on current TNT regimens (per the Modalities section below): oxaliplatin is used as part of the chemotherapy component of TNT (CAPOX/FOLFOX before/after CRT), not added concurrently to the radiotherapy itself, so this inconsistency doesn't directly bear on current standard TNT regimen choice — but is worth flagging given the wiki's practice of surfacing rather than silently resolving such discrepancies.

Pathologic complete response (pCR) as a surrogate endpoint — limitations

Per ASCRS Ch26 - Rectal Cancer Neoadjuvant Therapy: pCR is widely used as a trial endpoint and as a clinical trigger for considering NOM (see Surgery and NOM below), but the chapter cautions that pCR is an imperfect surrogate for long-term oncologic outcome — a pCR does not guarantee freedom from micrometastatic disease, and the correlation between achieving pCR and achieving durable disease-free or overall survival is imperfect at the individual-patient level even though it holds at a population level across the trials above. This corroborates and formalizes (rather than duplicates) the pCR/NOM-correlation caveat already noted below in Surgery and non-operative management, where the OPRA trial's TME-free survival rate was shown to exceed PRODIGE 23's pCR rate by >10 points — evidence in the other direction (patients achieving durable NOM success later than the standard pCR-assessment timepoint, without ever registering a formal pCR).

Why TNT over standard neoadjuvant CRT + adjuvant chemo

Compliance is much better neoadjuvantly: 80-90% of patients complete planned chemo before surgery, vs. only 25-50% completing adjuvant chemo after (perioperative complications, stoma, deconditioning all interfere with adjuvant dosing). This is possibly the single most practical argument for TNT, independent of the survival numbers.
Shortens total oncologic treatment time by ~1-2 months.
Early systemic therapy start plausibly better addresses micrometastatic disease that's already present at diagnosis (most distant relapses manifest within the first 2-5 years).

Efficacy

Now grounded in four trials' primary publications, not just the secondary review's Table 1, plus RAPIDO's own 5-year extended follow-up:

Trial	Design	n (TNT/ctrl)	pCR (TNT vs ctrl)	3y-DFS	OS	Locoregional recurrence
Bahadoer 2021 - RAPIDO Trial (3y) / Dijkstra 2023 - RAPIDO 5-Year Locoregional Failure (5.6y)	SCRT → 6xCAPOX/9xFOLFOX4 → TME, vs CRT → TME ± adjuvant	462/450 (460/446 in 5y LRR analysis)	28% vs 14%	(3y-DrTF 23.7% vs 30.4%; 5y-DrTF 27.8% vs 34.0%, HR 0.79, P=0.048)	3y-OS 89.1% vs 88.8% (NS); 5y-OS 81.7% vs 80.2% (HR 0.91, P=0.50, NS)	LRR after R0/R1 resection: 10.2% vs 6.1% at 5.6y, P=0.027 — significant, TNT worse (not significant at the original 3y analysis)
Conroy 2024 - PRODIGE 23 Long-Term Results	6x mFOLFIRINOX → CRT → TME → adjuvant, vs CRT → TME → adjuvant	231/230	28% vs 14%¹	7y-DFS 67.6% vs 62.5%	7y-OS 81.9% vs 76.1% (p=.033)	5.3% vs 8.1% at 7y — TNT numerically better
Jin 2022 - STELLAR Trial	SCRT → 4xCAPOX → TME → 2xCAPOX, vs CRT → TME → 6xCAPOX	302/297	21.8% vs 12.3%²	3y-DFS 64.5% vs 62.3% (noninferior)	3y-OS 86.5% vs 75.1% (secondary, non-powered)	8.4% vs 11.0% at 3y — TNT numerically better
Ciseł 2019 - POLISH II Long-Term Results	SCRT → 3xFOLFOX4 → TME, vs CRT (50.4Gy+oxaliplatin) → TME — higher-risk cT4/fixed-cT3 population	261/254	16% vs 12% (ypT0N0, NS)	8y-DFS 43% vs 41% (HR 0.95, NS)	8y-OS 49% vs 49% (HR 0.90, NS) — early 3y OS edge for TNT (9%) did not persist	35% vs 32% cumulative local failure at 8y (HR 1.08, NS) — no difference either direction

¹ PRODIGE 23's pCR figure is from the original 3-year primary publication (Conroy 2021, not independently ingested), reproduced in the long-term follow-up paper's discussion; not itself re-reported as a headline number in the long-term paper. ² Figure is pCR + sustained clinical complete response combined, not pCR alone.

DFS/MFS/distant-metastasis reduction is consistent across the three trials that showed a benefit (RAPIDO, PRODIGE 23, STELLAR) — TNT reliably reduces distant recurrence risk vs standard CRT in those. POLISH II, testing a similar SCRT+consolidation-chemo design in a higher-risk cT4/ fixed-cT3 population, showed no DFS or distant-metastasis benefit — a genuine outlier worth keeping in mind before treating "TNT reduces distant recurrence" as universal across all populations and regimens.
OS benefit is trial-dependent, not universal. PRODIGE 23 (chemotherapy-first design, same CRT in both arms) shows a clear, mature 7-year OS benefit. STELLAR shows a numerically favorable but statistically non-powered OS trend at only 35 months' follow-up. RAPIDO (SCRT-substitution design) shows no OS benefit at 3 years, which its own discussion attributes partly to an "ATRESS phenomenon" (shorter survival after metastatic relapse in the TNT arm) — a phenomenon PRODIGE 23's authors explicitly checked for and did not find in their own data — and this remains true at 5.6 years' follow-up (HR 0.91, P=0.50). POLISH II shows no OS difference at 8 years, after an early 3-year advantage for the short-course/consolidation-chemo arm that did not persist — a useful cautionary example of an early survival signal that later washed out with longer follow-up.
The locoregional-recurrence trade-off is now confirmed as a real, RAPIDO-specific finding — not a class effect of TNT, and not resolved to a single directional conclusion across trials. At RAPIDO's original 3-year analysis this was a numerical, non-significant trend; at 5.6 years' follow-up (Dijkstra 2023 - RAPIDO 5-Year Locoregional Failure) it became statistically significant (LRR 10.2% vs 6.1% after R0/R1 resection, P=0.027), with intraoperative mesorectal breach, positive CRM, tumor deposits, and higher ypN-stage as independent correlates — the authors speculate (but do not prove) that RAPIDO's long overall treatment time (~40 weeks EXP vs ~25 weeks STD) may yield a more fragile/fibrotic mesorectal specimen. PRODIGE 23 and STELLAR's TNT arms continue to show numerically better local control than CRT, and POLISH II shows no difference in either direction. Both STELLAR and RAPIDO use SCRT-based TNT regimens, so the trade-off isn't simply explained by SCRT vs chemotherapy-first design. Do not treat "TNT trades distant control for local control" as an established generalization across the class — it is now a well-confirmed finding specific to RAPIDO's regimen/population/treatment-time profile, not observed in PRODIGE 23, STELLAR, or POLISH II.
pCR (pathologic complete response) roughly doubled vs CRT alone in RAPIDO, PRODIGE 23, and STELLAR, to ~22-28% in the TNT arms — the key enabler of NOM, though pCR rate and successful long-term NOM are not tightly correlated (see NOM section). POLISH II's ypT0N0 rate (16% vs 12%) was not significantly different between arms.
Toxicity: RAPIDO and STELLAR both showed higher acute grade ≥3 toxicity with TNT during the preoperative phase (RAPIDO 48% vs 25%; STELLAR 26.5% vs 12.6%, mostly hematologic) — real practical cost not fully captured by the efficacy headline numbers. Treatment-related death rates were low and similar between arms across trials.
A related but distinct trial, Schrag 2023 - PROSPECT Trial, tests the opposite strategy — omitting radiotherapy for good responders in a lower-risk, sphincter-sparing-eligible population (not a TNT trial in this concept's sense) — see its source page and the Indications table below.

Indications — risk-stratified, not blanket

Tumor profile	TNT indicated?
T4, N2, MRF+ (mesorectal fascia involved), or EMVI+ (extramural vascular invasion)	Yes — clearest indication
T3N1	Consider, based on other risk factors
T3N0, upper/mid rectum, favorable histology	Usually no benefit — standard (chemo)RT or nothing may suffice
T3N0, distal rectum	TNT worth considering specifically for organ-preservation/NOM potential — highest pCR rates, biggest QoL payoff (avoids permanent colostomy)
Stage I	Investigational only — unclear benefit over standard CRT; NOM burden may not be justified if surgery alone would cure without permanent colostomy
Oligometastatic (stage IV, resectable mets)	Reasonable extrapolation, but evidence is sparse — no dedicated large trials yet
MMRd/MSI tumors (~5% of rectal cancers)	Different pathway entirely — immunotherapy (PD-1/PD-L1 inhibitors: ipilimumab+nivolumab, dostarlimab, etc.) achieves 60-100% pCR, even without radiotherapy. Chemo-based TNT not recommended for this subgroup. MMRd/MSI testing should be done before neoadjuvant therapy decisions.

Modalities

Radiotherapy — two regimens, no proven superiority of one over the other in the TNT setting:

CRT (long-course chemoradiotherapy): 45Gy/25fx to tumor+mesorectum+nodes over 5 weeks, boost to 50Gy, + concurrent capecitabine. Better-predictable late toxicity (normofractionation); preferred for very advanced tumors (T4/MRF+), borderline-performance-status patients, and NOM candidates.
SCRT (short-course): 25Gy/5fx over 1 week. Lower total equivalent dose; convenient, doesn't delay systemic chemo; may be preferred when high risk of/present metastatic disease. Possible (unproven) higher late local relapse rate vs. CRT. Corroborated by a Washington University pilot study and a UK phase II study of SCRT + systemic chemotherapy (per ASCRS Ch26 - Rectal Cancer Neoadjuvant Therapy, textbook-secondary-source-level, not independently ingested) — both smaller, earlier-stage evidence for the SCRT+chemo approach that Bahadoer 2021 - RAPIDO Trial and Jin 2022 - STELLAR Trial later tested definitively. The chapter also describes a Polish Colorectal Study Group comparison of short-course RT+FOLFOX vs. long-course CRT with 7-year follow-up — this is the same trial already ingested in primary- literature depth as Ciseł 2019 - POLISH II Long-Term Results (see Efficacy above); treated as corroboration, not duplicated.

Chemotherapy — CAPOX or FOLFOX6 standard (3-4 months = optimal TNT length; no evidence longer helps). FOLFOXIRI/FOLFIRINOX (add irinotecan) is more intensive, reasonable for very-high-risk/ oligometastatic disease as conversion therapy, but hasn't proven superior to CAPOX/FOLFOX by direct randomized comparison — Alvarez 2024 - JANUS Trial Protocol (Alliance A022104/NRG-GI010) is testing triplet (mFOLFIRINOX) vs doublet (mFOLFOX6/CAPOX) specifically as consolidation chemo after long-course CRT, powered for clinical complete response (phase II) and DFS (phase III); still accruing (330/760 as of May 2024), no results yet. Separately, Brouquet 2020 - GRECCAR16 Trial Protocol (NORAD01-GRECCAR16) is testing modified FOLFIRINOX as a replacement for radiotherapy entirely (not consolidation) in CRM-negative resectable LARC — also no results yet. Oxaliplatin-based regimens carry more toxicity in patients >70-75yo or with major comorbidities — individualize.

Targeted therapy (bevacizumab, cetuximab/panitumumab) — not currently recommended outside trials; results equivocal, increased toxicity (bevacizumab: healing problems, fistula risk — must be held 4-6 weeks before surgery and around radiotherapy). Quantified per Preoperative Evaluation & Perioperative Risk Optimization (ASCRS Ch6): a 797-patient study found bevacizumab exposure associated with OR 2.85 for anastomotic leak; a smaller 78-patient study using a median 9-week interval from last bevacizumab dose to surgery still saw anastomotic leaks in 6 patients (4 requiring re-laparotomy). Current recommendation there is to hold antiangiogenic agents ≥6 weeks before major surgery — consistent with, and slightly more conservative than, the "4-6 weeks" figure already on this page.

Immunotherapy — first-line for MMRd/MSI tumors (see indications table above); optimal duration unclear (2 weeks-6 months across studies).

Sequence and timing

No clearly defined optimal sequence; radiotherapy-first may give more time for local response to manifest and is favored for very advanced/bleeding tumors or NOM intent. Chemotherapy-first may suit high distant-metastatic-risk patients (immediate systemic control).
Gap between modalities kept short (~10-14 days) to allow acute-toxicity recovery without letting resistant clones regrow.
Surgery typically 3-6 weeks after chemo, 4-10 weeks after radiotherapy (or immediately after SCRT). Evidence for optimal interval is weak; longer intervals allow fuller response but also more time for regrowth of resistant cells — if a longer interval is chosen, re-stage before surgery.

Consolidation vs. induction chemotherapy sequencing

A finer-grained sequencing question than "radiotherapy-first vs. chemotherapy-first" above: when a TNT regimen combines CRT with a full course of systemic chemotherapy, should the chemotherapy be given before CRT (induction) or after CRT, before surgery (consolidation)? Per ASCRS Ch26 - Rectal Cancer Neoadjuvant Therapy, not independently ingested from primary publications on this wiki (textbook-secondary-source-level):

Consolidation chemotherapy originates from Habr-Gama's original watch-and-wait work — her original regimen, and a later refined regimen, both added chemotherapy after CRT specifically to maximize the tumor-response window before response assessment, on the logic that response continues to evolve for weeks after radiotherapy completes.
The Timing of Rectal Cancer Response to Chemoradiation Consortium studied how response continues to evolve over time after CRT completion — supporting the rationale for a consolidation window rather than assessing response (or proceeding straight to surgery) immediately after CRT.
KONCLUDE and the Spanish GCR-3 trial both bear on consolidation-chemotherapy regimen design.
The MSKCC TNT retrospective cohort (reported as approximately 320 induction-sequence vs. 331 consolidation-sequence patients) is one of the larger comparisons of the two sequences; reported outcomes favored (or at minimum did not disadvantage) consolidation sequencing for achieving pCR/complete-response rates, consistent with the rationale above, though this is a retrospective, not randomized, comparison.
The Rectal Cancer Consortium induction-vs-consolidation trial and German CAO/ARO/AIO-12 are the more direct randomized comparisons of induction vs. consolidation sequencing within a TNT framework; AIO-12 reportedly favored consolidation chemotherapy on its pCR-based primary endpoint.

Net practical takeaway (consistent with, and now better sourced than, this page's existing regimen descriptions above, which already default to SCRT/CRT → chemotherapy → surgery, i.e. a consolidation sequence for the SCRT-based regimens): the evidence reported in this chapter leans toward consolidation sequencing when a choice must be made, though the comparison is not settled to the same evidentiary standard as the headline TNT-vs-CRT trials above (AIO-12 is the only directly randomized head-to-head trial reported here, and it is not independently ingested from its primary publication on this wiki).

Surgery and non-operative management (NOM)

Standard surgery: low anterior resection (LAR) or abdominoperineal resection (APR), with total mesorectal excision (TME). No significant difference in R0 rate (~90%+), Clavien-Dindo complications, or LARS between TNT and standard arms.
NOM ("watch and wait"): offered to patients with complete/near-complete clinical response, assessed 4-8 weeks post-TNT by DRE + endoscopy + MRI (MSK three-tiered scheme). Requires a highly competent multidisciplinary team and a well-informed, compliant patient willing to undergo intensive surveillance. Repeat biopsy after TNT is not recommended (false pos/neg risk, healing complications). Full WW protocol detail — terminology, patient/tumor selection criteria, the three-tier response classification, surveillance schedule, local regrowth/systemic-recurrence risk, oncologic/functional outcomes, and response-prediction research — now lives on Watch and Wait (Nonoperative Management) (per ASCRS Ch28 - Rectal Cancer Nonoperative Management); this page's own figures below remain the primary-literature-sourced authority for locoregional/distant relapse rates specifically.
Locoregional relapse on surveillance: ~20-40%, most salvageable by radical surgery without DFS penalty.
Distant metastatic risk while on surveillance: 5-15%, mostly associated with locoregional recurrence — this is the main real risk of NOM and should be discussed candidly with patients.
pCR rate and NOM success aren't tightly correlated — OPRA trial's 3-year TME-free survival (41-50%, depending on sequence) exceeded PRODIGE 23's pCR rate (28%) by >10 points, suggesting some patients achieve complete response later than the standard pCR-assessment timepoint.

Adjuvant therapy after TNT

Not indicated if the full neoadjuvant course (3-4 months, ideally 4) was completed — splitting chemo pre/post-op with a perioperative gap plausibly lowers total dose intensity and may promote resistance. Exceptions: R1-2 resections (3 months adjuvant reasonable), or patients who didn't complete ≥3 months of neoadjuvant chemo (adjuvant capecitabine ×3mo as a fallback).

For patients treated with the conventional (non-TNT) sequence instead — neoadjuvant radiation followed by surgery, adjuvant chemotherapy given afterward — see Adjuvant Chemotherapy for Colorectal Cancer's Adjuvant chemotherapy following neoadjuvant radiation section: two RCTs (ADORE, German CAO/ARO/AIO-04) show a modest DFS benefit from adjuvant FOLFOX over 5-FU/leucovorin in this setting, but a ~1200-patient meta-analysis found no OS/DFS/ distant-recurrence benefit from adding any 5-FU-based adjuvant chemotherapy after neoadjuvant CRT — part of the treatment-interruption/incomplete-course problem (only ~50% of patients complete the full prescribed adjuvant course without interruption) that motivated moving chemotherapy forward into the TNT sequence in the first place.

Risk-based approach (summary of the review's Fig. 1 algorithm)

Stratifies by age (>40 vs <40), tumor location, histologic grade, MSS/MMRp vs MSI/MMRd, T-stage, and N-stage into four broad pathways:

Locally advanced, obstructing/bleeding → CRT or SCRT → CAPOX/FOLFOX6 → surgery
Locally advanced + high risk of distant mets → SCRT → CAPOX/FOLFOX6 (or interleaved)
High risk of / manifest distant mets → CAPOX/FOLFOX6/FOLFOXIRI → SCRT (chemo-first)
MSI/MMRd → SCRT + ICI, or ICI alone

Open items / gaps

RAPIDO, PRODIGE 23, STELLAR, and POLISH II primary publications are now all ingested (2026-08-20), along with RAPIDO's 5-year extended follow-up. The comparison table above now has four independent trials.
The locoregional-recurrence trade-off question (previously flagged unresolved) is now answered for RAPIDO specifically: Dijkstra 2023 - RAPIDO 5-Year Locoregional Failure confirms a statistically significant increase in LRR with TNT at 5.6 years. It remains a RAPIDO-specific finding, not observed in PRODIGE 23, STELLAR, or POLISH II — see Efficacy above for the full synthesis. This should be revisited only if further comparative literature (e.g. a formal meta-analysis across all four trials) is ingested.
Rectal Cancer is no longer a stub — since expanded with staging, TME/CRM/downstaging history, and survival by stage (via the Sabiston Rectal Cancer Surgery chunk) — but MRF and EMVI specifically, referenced here as TNT risk-stratification criteria, still aren't independently defined with their own detail anywhere in the wiki.
JANUS and NORAD01-GRECCAR16 protocols are now ingested (Alvarez 2024 - JANUS Trial Protocol, Brouquet 2020 - GRECCAR16 Trial Protocol) — both are still accruing/awaiting results, so the substantive triplet-vs-doublet-consolidation and chemotherapy-vs-radiotherapy-omission questions remain open. ACO/ARO/AIO-18 (CRT vs. SCRT head-to-head) and GRECCAR 14 are still referenced only secondhand (via the Boublikova review and PRODIGE 23's long-term discussion, respectively) — worth ingesting their protocols or results if/when available.
Schrag 2023 - PROSPECT Trial (radiation-omission in lower-risk LARC) is now ingested and referenced above — worth a fuller writeup on Rectal Cancer's treatment-selection section if that page is expanded further to cover treatment individualization by risk group.
Foundational-trial history, concurrent-chemoradiation-regimen evidence, and consolidation-vs- induction sequencing are now ingested (2026-08-24, via ASCRS Ch26 - Rectal Cancer Neoadjuvant Therapy) — see the new History and foundational trials, Concurrent chemoradiation regimen trials, pCR-as-surrogate-endpoint, and Consolidation vs. induction chemotherapy sequencing sections above. None of the newly-named trials in these sections (Swedish Rectal Cancer Trial, Dutch Colorectal Cancer Group trial, original Polish trial, TROG, Stockholm III, FOWARC, Lyon R0-04, CALGB 89901, ECOG 3204, STAR-01, NSABP R-04, German CAO/ARO/AIO-04, Habr-Gama's regimens, KONCLUDE, GCR-3, the MSKCC TNT cohort, the Rectal Cancer Consortium induction-vs-consolidation trial, German CAO/ARO/AIO-12) are independently ingested from their own primary publications — all textbook-secondary-source-level, a natural next-ingest target if any individual trial's full data becomes needed.
Open, unresolved cross-trial inconsistency: STAR-01 and NSABP R-04 found no DFS benefit (plus added toxicity) from adding oxaliplatin to fluoropyrimidine-based CRT, while German CAO/ARO/AIO-04 reportedly found a DFS benefit from the same addition — see the flag in Concurrent chemoradiation regimen trials above. Not resolved here; would need each trial's primary publication to adjudicate.

Colorectal LLM Wiki